GlassScriptPhysician profile
Etan Spira
NPI 1003011891
$3,173.19
in general payments reported to CMS, 2019-2025
35 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $419 · 2021: $386 · 2022: $542 · 2023: $509 · 2024: $477 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.80 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $324.51 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.37 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $198.03 | 2020-2025 | |
| Janssen Biotech, INC. | $163.53 | 2019-2025 | Stelara, Simponi Aria, Remicade |
| Eisai INC. | $112.26 | 2020 | |
| Ardelyx, INC. | $110.58 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $85.88 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $83.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Laborie Medical Technologies Corp. | $68.41 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $63.66 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $55.02 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $53.45 | 2022-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $52.15 | 2019-2023 | Dificid |
| Boston Scientific Corporation | $48.78 | 2024 | Spyglass |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $37.56 | 2024-2025 | Evis X1 Video System Center, Hanarostent Esophagus Tts(Ccc) |
| Celgene Corporation | $29.38 | 2022-2024 | Zeposia |
| Ucb, INC. | $28.32 | 2019 | |
| Pfizer INC. | $28.18 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $23.03 | 2024 | Abc Balloons |
| Novo Nordisk INC | $22.85 | 2025 | Wegovy |
| Capsovision, INC. | $22.56 | 2025 | Capsocam Plus |
| W. L. Gore & Associates, INC. | $19.19 | 2020 | |
| Lilly USA, LLC | $17.49 | 2025 | Omvoh |
| Celltrion USA INC. | $16.67 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $15.95 | 2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $15.24 | 2024 | Terlivaz |
| Allergan, INC. | $15.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.67 | 2024 | Rebyota |
| Organon LLC | $14.50 | 2023 | Renflexis |
| Exact Sciences Corporation | $14.19 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $14.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.05 | 2019 | |
| Redhill Biopharma INC. | $12.50 | 2020 | |
| Shionogi INC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Etan Spira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.